Stocktoria
TG THERAPEUTICS, INC. TGTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1995-12-14
TG THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M | $6.7M |
| R&D expense | $160.2M | $94.3M | $76.2M | $125.4M | $222.6M |
| SG&A expense | $232.0M | $154.3M | $122.7M | $95.5M | $128.1M |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M | -$344.8M |
| Interest expense | — | — | $12.6M | $10.2M | $5.6M |
| Income tax | -$339.8M | $2.2M | $390,000 | $0 | $0 |
| Net income | $447.2M | $23.4M | $12.7M | -$223.8M | -$348.1M |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 |
| Operating cash flow | -$24.8M | -$40.5M | -$31.4M | -$176.2M | -$295.6M |
| Free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M | -$296.0M |
| Cash & equivalents | $79.1M | $179.9M | $92.9M | $102.3M | $298.9M |
| Inventory | $125.6M | $110.5M | $39.8M | $0 | — |
| Total assets | $1.1B | $577.7M | $329.6M | $193.6M | $379.6M |
| Total liabilities | $415.2M | $355.3M | $169.1M | $135.0M | $142.5M |
| Shareholders' equity | $648.0M | $222.4M | $160.5M | $58.6M | $237.2M |
Source: SEC EDGAR filings · CIK 0001001316 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.